Detalles de la búsqueda
1.
Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum.
Curr Oncol Rep
; 26(1): 65-79, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38180692
2.
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
Curr Oncol Rep
; 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38652426
3.
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cancer
; 128(16): 3067-3079, 2022 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35727053
4.
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers.
Oncologist
; 25(10): e1509-e1515, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32735386
5.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474768
6.
Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer.
Support Care Cancer
; 28(10): 4687-4695, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31960124
7.
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer.
N Engl J Med
; 382(9): 874-875, 2020 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32101673
8.
Treatment and prognostic factors of patients with thymic epithelial tumors at first recurrence or progression.
Future Oncol
; 13(27): 2429-2439, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29121777
9.
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.
Clin Exp Metastasis
; 41(2): 117-129, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38363410
10.
Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.
Anticancer Drugs
; 24(2): 99-111, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23165435
11.
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.
Minerva Urol Nephrol
; 75(3): 308-318, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36511379
12.
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis.
Front Oncol
; 13: 1163768, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37324003
13.
One-year nutrition counselling in the context of a Mediterranean diet reduced the dietary inflammatory index in women with breast cancer: a role for the dietary glycemic index.
Food Funct
; 14(3): 1560-1572, 2023 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36655860
14.
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.
iScience
; 26(11): 107970, 2023 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37860695
15.
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study.
Transl Lung Cancer Res
; 11(1): 87-99, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35242630
16.
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
Int Immunopharmacol
; 110: 108985, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35777264
17.
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
Eur J Cancer
; 163: 55-65, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35042068
18.
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
Clin Genitourin Cancer
; 20(2): 155-164, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35000876
19.
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
Thorac Cancer
; 13(3): 483-488, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34939342
20.
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
J Immunother Cancer
; 10(2)2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35173031